OpenAI ships GPT‑Rosalind

Drug discovery is slow and expensive, and OpenAI said on April 16 it is releasing GPT‑Rosalind to help biology teams do more of the early research work faster. (openai.com) OpenAI described GPT‑Rosalind as a “frontier reasoning model” for biology, drug discovery and translational medicine, and said it is available as a research preview in ChatGPT, Codex and the application programming interface for qualified customers. (openai.com) The company said the model is built for tasks such as target discovery, target validation, genomics interpretation, pathway analysis, literature synthesis and hypothesis generation. OpenAI said scientists can use it to query databases, read papers, use scientific tools and suggest experiments. (openai.com) (usnews.com) Biology research starts with a basic problem: scientists have to connect papers, lab data, gene readouts and chemical information before they can even decide what to test. OpenAI said those workflows are often fragmented and hard to scale across teams. (openai.com) That bottleneck sits at the front of a drug pipeline that OpenAI said typically takes about 10 to 15 years to move from target discovery to regulatory approval in the United States. The company said better work at that stage can improve target selection, biological hypotheses and experiment quality downstream. (openai.com) OpenAI is not selling this as a consumer science bot. The company said GPT‑Rosalind is currently limited to eligible U.S. customers with Enterprise agreements, requires legitimate biology research use cases and is not available for customer-facing products or external commercial applications. (openai.com) OpenAI also tied the launch to enterprise controls. The company said the product runs with ChatGPT Enterprise, Codex and the application programming interface, and includes governance features such as SOC 2 Type 2, HIPAA-aligned standards and a pledge not to train on customer data. (openai.com) The release extends a broader shift in artificial intelligence from general-purpose chatbots to industry-specific systems sold to large organizations. Reuters reported that OpenAI this week also introduced GPT‑5.4‑Cyber, a model tuned for defensive cybersecurity work. (usnews.com) Drug research has become one of the busiest targets for that strategy. Fierce Biotech, citing PitchBook, reported that more than $17 billion has been invested in artificial-intelligence-driven drug discovery since 2019, even though AI-developed drugs have not yet reached large-scale trials. (fiercebiotech.com) OpenAI said it is already working with Amgen, Moderna, the Allen Institute and Thermo Fisher Scientific, and it launched a free Life Sciences research plugin for Codex that connects to more than 50 scientific tools and data sources. For now, GPT‑Rosalind looks less like a replacement for scientists than a new layer of software around the work they already do. (openai.com)